Detalles de la búsqueda
1.
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
Clin Infect Dis
; 78(4): 983-990, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633256
2.
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
Antimicrob Agents Chemother
; 66(5): e0222321, 2022 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35491829
3.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Clin Infect Dis
; 73(1): 33-42, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33336698
4.
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Clin Infect Dis
; 70(7): 1344-1352, 2020 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31121015
5.
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Clin Infect Dis
; 70(7): 1336-1343, 2020 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31121013
6.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Clin Infect Dis
; 68(4): 535-544, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30184165
7.
Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate.
Antimicrob Agents Chemother
; 63(12)2019 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31548188
8.
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.
J Infect Dis
; 215(11): 1725-1733, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28431010
9.
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).
Clin Infect Dis
; 65(3): 442-452, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28369211
10.
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Antimicrob Agents Chemother
; 59(7): 3816-22, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25870057
11.
Reply to Lanzafame et al.
Clin Infect Dis
; 69(10): 1832-1833, 2019 10 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30891586
12.
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
J Antimicrob Chemother
; 69(3): 573-81, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24128669
13.
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Antimicrob Agents Chemother
; 57(11): 5500-8, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23979732
14.
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
J Acquir Immune Defic Syndr
; 91(1): 68-72, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35972855
15.
Changes in weight and BMI with first-line doravirine-based therapy.
AIDS
; 35(1): 91-99, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33048879
16.
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Lancet HIV
; 8(6): e324-e333, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000227
17.
Rational Design of Doravirine: From Bench to Patients.
ACS Infect Dis
; 6(1): 64-73, 2020 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31621289
18.
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
J Acquir Immune Defic Syndr
; 85(5): 635-642, 2020 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32925358
19.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Lancet HIV
; 7(1): e16-e26, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31740348
20.
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
J Acquir Immune Defic Syndr
; 81(4): 463-472, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30985556